Evidence map›Paper›PMID 31571853›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2019

Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial.

Kentaro Machida, Tomotaka Kawayama, Masaharu Kinoshita, Masakazu Ichinose, Tohru Tsuda, Shohei Takata, Hiroshi Koto, Makoto Yoshida, Yoshinori Ashihara, Masaru Kawashima and 2 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Kentaro Machida *Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0000-0002-9394-091X
Tomotaka Kawayama *Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.ORCID 0000-0002-9537-4229
Masaharu Kinoshita *Nagata Hospital, Yanagawa 832-0059, Japan.
Masakazu IchinoseDepartment of Respiratory Medicine, Tohoku University, Graduate School of Medicine, Sendai 980-8574, Japan.
Tohru TsudaKirigaoka Tsuda Hospital, Kitakyushu 802-0052 Japan.ORCID 0000-0002-3867-8322
Shohei TakataDivision of Respiratory Medicine, National Hospital Organization Fukuoka-Higashi Medical Center, Koga 811-3195, Japan.
Hiroshi KotoDivision of Respiratory Medicine, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan.ORCID 0000-0001-9855-3321
Makoto YoshidaDivision of Respiratory Medicine, National Hospital Organization Fukuoka Hospital, Fukuoka 811-1394, Japan.
Yoshinori AshiharaDivision of Respiratory Medicine, Oita Nakamura Hospital, Oita 870-0022, Japan.
Masaru KawashimaONO Pharmaceutical Co. Ltd., Osaka 541-8564, Japan.
Hideaki SunaONO Pharmaceutical Co. Ltd., Osaka 541-8564, Japan.
Hiromasa InoueDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0000-0001-8080-3812
Kagoshima University · JPOno Pharmaceutical (Japan) · JPFukuoka Higashi Medical Center · JPFukuoka Hospital · JPKurume University · JPKyushu Central Hospital of the Mutual Aid Association of Public School Teachers · JPNakamura Memorial Hospital · JPTohoku University · JPTsuda University · JPYanagawa Rehabilitation Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although long-acting muscarinic receptor antagonists are central to the management of chronic obstructive pulmonary disease (COPD), inhaled medicines may have technical difficulty in some patients and adherence barriers. Methods: A multicenter, randomized, double-blind, placebo-controlled 3×3 crossover Phase II trial was performed to evaluate the efficacy and safety of oral administration of the antimuscarinic agent imidafenacin in patients with COPD. Twenty-seven male COPD patients with % forced expiratory volume in 1 s (FEV Results: Maximum change in FEV Conclusion: A single oral dose of imidafenacin 0.1 mg or imidafenacin 0.2 mg may contribute to the improvement of pulmonary function with excellent safety and tolerability in patients with COPD. Trial registration: JapicCTI-121760 (Japan Pharmaceutical Information Center - Clinical Trials Information [JapicCTI]; http://www.clinicaltrials.jp/user/cteSearch_e.jsp).

Indexed as

Administration, OralAgedCross-Over StudiesDouble-Blind MethodHumansImidazolesLungMaleMiddle AgedMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveTreatment OutcomeimidafenacinImidazolesMuscarinic Antagonistsanti-cholinergicbronchodilatorCOPDimidafenacinlung function

Identifiers

PMID31571853
PMCPMC6757323
OpenAlexW2973592317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.